Libra Study© for Trigeminal Neuralgia

Who qualifies?
If you are an adult between the ages of 18-75 who suffers from primary or idiopathic trigeminal neuralgia and who is not fully benefitting from your current therapies, this study may be an option for you.
 
Study summary description
The study may last up to 20 weeks (about 4 and a half months) with visits occurring every week for 8 weeks (about 2 months) and then every two weeks after that through week 20. In addition, there is the possibility of a 12-month extension with visits occurring every 12 weeks (about 3 months).
 
If you qualify for the study, you will be expected to take the medication daily, by mouth, complete a pain diary, and attend study visits in clinic as well completing assessments remotely e.g., from home. You may be compensated for your time and travel.
 
Who is Noema Pharma?
Noema Pharma initiated the Libra Study© to evaluate the effect of basimglurant for the management of pain in patients with trigeminal neuralgia. A biotech company based in Switzerland, Noema Pharma is developing groundbreaking therapies to address the most debilitating symptoms in rare diseases of the brain and nervous system.
 
Need additional information?
More information on the study assessments and inclusion criteria is available on the ClinicalTrials.gov website (Study NCT05217628). A list of enrolling sites is also available on the website.

Libra Study© Locations

Noema Pharma is based in the United States and Switzerland.

Click to download contact information for US sites.

Kaizen Brain Center

Dr. Hossein Ansari, Principal Investigator

Contact: Melissa Escamirosa

Call 858-294-0161

Email [email protected]

University of Cincinnati

Dr. Reena Shah, Principal Investigator

Contact: Alexandra Ramirez

Call 513-558-1707

Email [email protected]

University of South Florida

Dr. Amanda Moore, Principal Investigator

Contact: Allyssa Sawyer, B.S.

Call 813-396-2736

Email [email protected]

Columbia University Irving Medical Center

Dr. Raymond Sekula, Principal Investigator

Contact: Angela Valazquez

Call 212-304-7167

Email [email protected]

Disclaimer

The Facial Pain Association (FPA) is enthusiastic about medical research and encourages those with neuropathic facial pain, including trigeminal neuralgia, and related healthcare conditions to consider participation.  It is important to note, however, that the FPA is not offering, nor is it qualified to offer, a scientific or medical endorsement of any Institutional Review Board (IRB) approved patient study. An IRB is a committee established to review and approve research involving human subjects. The purpose of the IRB is to ensure that all human subject research is conducted in accordance with all federal, institutional, and ethical guidelines. All studies and trials listed have IRB or Ethics Committee approval where relevant. The study’s safety and scientific validity is the sole responsibility of the study sponsors and investigators.   Patients should use the contact information provided to contact the research organization for more information.   

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your healthcare provider. Although study sponsors may donate to the FPA, or support the FPA through advertising or corporate sponsorship, such support does not influence or guide our decision about the studies we identify.  

Noema Pharma is a sponsor of the Facial Pain Association.